.
MergerLinks Header Logo

New Deal


Announced

Dr. Reddy's to acquire anti-allergy brands from Glenmark Pharmaceuticals.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Uzbekistan

mometasone

Pending

Private

Kazakhstan

Acquisition

Russian Federation

Pharmaceuticals

Ukraine

azelastine

Single Bidder

Cross Border

Friendly

Majority

allergy solutions

Synopsis

Edit

Dr. Reddy's Laboratories, an integrated pharmaceutical company, agreed to acquire anti-allergy brands from Glenmark Pharmaceuticals, a pharmaceutical company. Financial terms were not disclosed. Under the terms of the agreement, Dr. Reddy's will acquire Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine). “The new brands are a great addition to our product portfolio in Russia, Ukraine, Kazakhstan and Uzbekistan which are important core markets for us. Momat Rino, the largest brand acquired, has recently received OTC registration in Russia and this will enable accelerated access of this product to patients. The acquired products will further add to Dr. Reddy’s strong presence in the anti-allergy segment in these countries, and will also enable us to offer a more comprehensive solution to patients in this area.” M V Ramana, Dr. Reddy's Chief Executive Office.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US